Multiple Myeloma
Item
patients previously diagnosed with mm based on criteria from the international myeloma working group (imwg)
boolean
C0026764 (UMLS CUI [1])
Measurable Disease
Item
patients who have 'measurable' disease
boolean
C1513041 (UMLS CUI [1])
Age | Informed Consent
Item
age 18 years at the time of signing informed consent
boolean
C0001779 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
Therapeutic procedure Additional Multiple Myeloma | Remission Induction Therapy | Study Subject Participation Status
Item
a patient may have received up to 4 months of other anti myeloma therapy, as part of the induction therapy, prior enrollment and still be considered eligible to participate in the study, as long as the patient's multiple myeloma has not progressed on the current regimen and the other eligibility criteria are met.
boolean
C0087111 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C0026764 (UMLS CUI [1,3])
C1514832 (UMLS CUI [2])
C2348568 (UMLS CUI [3])
t(4;14) Positive
Item
patient is t(4;14) positive on screening assay.
boolean
C2986942 (UMLS CUI [1,1])
C1514241 (UMLS CUI [1,2])
Pharmacotherapy | Adrenal Cortex Hormones | Prednisone U/day | Therapeutic procedure Myeloma | Therapeutic radiology procedure Excluded | Remission Induction Therapy Excluded
Item
concomitant therapy medications that include corticosteroids (> 10 mg per day of prednisone or equivalent) or other therapy that is or may be active against myeloma prior to day 1 (with the exception of radiation therapy or induction therapy as described under the above inclusion criteria section
boolean
C0013216 (UMLS CUI [1])
C0001617 (UMLS CUI [2])
C0032952 (UMLS CUI [3,1])
C0456683 (UMLS CUI [3,2])
C0087111 (UMLS CUI [4,1])
C0026764 (UMLS CUI [4,2])
C1522449 (UMLS CUI [5,1])
C2828389 (UMLS CUI [5,2])
C1514832 (UMLS CUI [6,1])
C2828389 (UMLS CUI [6,2])
Peripheral Neuropathy CTCAE Grades
Item
peripheral neuropathy of grade 2 or greater.
boolean
C0031117 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
Mucosal bleeding | Internal hemorrhage | Platelet Transfusion refractory | Platelet count Maintenance Unable
Item
patients with evidence of mucosal or internal bleeding and/or refractoriness to platelet transfusions (i.e., unable to maintain a platelet count 50 x 109 /l).
boolean
C2748540 (UMLS CUI [1])
C1390214 (UMLS CUI [2])
C0086818 (UMLS CUI [3,1])
C0205269 (UMLS CUI [3,2])
C1287267 (UMLS CUI [4,1])
C0024501 (UMLS CUI [4,2])
C1299582 (UMLS CUI [4,3])
Absolute neutrophil count | Granulocyte Colony-Stimulating Factor | Granulocyte-Macrophage Colony-Stimulating Factor
Item
patients with an absolute neutrophil count (anc) < 1.0 x 109/l. treatment to raise the anc, such as granulocyte colony-stimulating factor (g-csf) or granulocyte-macrophage colony-stimulating factor (gm-csf) is not allowed within 14 days of study entry.
boolean
C0948762 (UMLS CUI [1])
C0079459 (UMLS CUI [2])
C0079460 (UMLS CUI [3])
Hemoglobin measurement | Transfusion
Item
patients with hemoglobin < 80 g/l despite transfusion.
boolean
C0518015 (UMLS CUI [1])
C1879316 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
pregnant or lactating women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])